Company Overview - Stoke Therapeutics is an early-stage biotechnology company focused on designing RNA-based therapeutics for severe genetic diseases, leveraging a proprietary platform [5] - The company has a market capitalization of $1.9 billion and reported a revenue of $184.4 million with a net income of -$6.9 million for the trailing twelve months [4] - The stock price has increased by 340% over the past year, indicating strong market performance [4] Transaction Summary - Arthur Tzianabos, the chair of Stoke Therapeutics, sold 4,355 shares of Common Stock for approximately $174,000 on March 10, 2026 [1][2] - Post-transaction, Tzianabos holds 31,339 shares directly, with a total direct ownership value of about $1.20 million [2] - The transaction was linked to the exercise of 3,955 stock options, suggesting it was a liquidity event related to equity compensation rather than a reduction in long-held equity [6] Clinical Development - Stoke Therapeutics is advancing its pipeline with lead clinical candidates STK-001 for Dravet syndrome and STK-002 for autosomal dominant optic atrophy, with STK-002 recently entering a Phase 1 study [7][9] - The company has published data indicating that its lead candidate, zorevunersen, shows lasting reductions in seizures and improvements in cognition and behavior for patients with Dravet syndrome, positioning it as a potential disease-modifying therapy [9] Investor Implications - The recent share sale by Tzianabos reflects compensation structures rather than a change in sentiment, as a significant portion of his holdings remains in stock options [8] - For long-term investors, the focus should be on the execution risks associated with clinical data and regulatory approval, as the current valuation is based on considerable success [10]

AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will formally introduce its Deciparticle™ nanomedicine platform and present its advancing clinical pipeline at BIO-Europe Spring 2026, where the company has been selected as a Presenting Company. The presentation will take place at: Event: BIO-Europe Spring 2026Session: Presenting Co ...

Core Insights - Entrada Therapeutics is advancing its RNA-based therapeutic pipeline, focusing on neuromuscular and ocular diseases, with significant data expected in 2026 [2][3] Clinical Development Pipeline - The company is on track to report data from the first cohort of the ELEVATE-44-201 study in Q2 2026 and from ELEVATE-45-201 in mid-2026 [1][3] - Entrada plans to initiate a global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and submit regulatory applications for ENTR-601-51 in 2026 [1][3] - The company has completed dosing of Cohort 1 for ENTR-601-44 and is transitioning to the open-label Phase 2 portion [3] - ENTR-801 has been selected as the first clinical candidate for treating Usher syndrome type 2A, with a second candidate expected to be nominated in 2026 [1][5] Financial Position - Entrada has a cash runway anticipated into Q3 2027, indicating strong financial health to support ongoing and future clinical programs [1][6] Upcoming Events - The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing its development progress [2][7]

Company Overview - Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products aimed at addressing high unmet medical needs in cancer and rare pediatric diseases [4]. - The company is led by Dr. Vuong Trieu, who has a strong intellectual property (IP) portfolio with over 500 patent applications and 75 issued patents [3][4]. Industry Context - The need for innovation in RNA-based, immunotherapy, and targeted therapeutics is critical, particularly for aggressive cancers like glioblastoma and pancreatic cancer, as well as pediatric rare diseases [2]. - Oncotelic Therapeutics is positioned among leading innovators in the cancer and rare disease treatment space, contributing to the industry's growth [3]. Strategic Positioning - Oncotelic Therapeutics is building a breakthrough portfolio that leverages AI, nanomedicine, and novel clinical models to reshape the biotech landscape [3]. - The company also engages in joint ventures, owning 45% of GMP Bio, which enhances its strategic position in oncology and rare disease therapeutics [4].

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on January 18, 2024. Registration No. 333-276467 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRANSCODE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) | Delaware | 2834 | 81-1065054 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorp ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on January 17, 2024. Registration No. 333-276467 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRANSCODE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) | Delaware 2834 | | 81-1065054 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorp ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on September 22, 2023. Registration No. 333-274251 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRANSCODE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 81-1065054 (Primary Standard Industrial Classification Code Number) ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on September 8, 2023. Registration No. 333-274251 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRANSCODE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) AMENDMENT NO. 1 TO Delaware 2834 81-1065054 (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation or organization) (Primary Standard Ind ...